Biora Therapeutics, Inc. (BIOR) Stock

About Biora Therapeutics, Inc.

Biora Therapeutics, Inc. is a biotechnology company focused on developing cutting-edge oral biotherapeutic solutions. The company's core efforts involve two main therapeutic programs: Targeted Therapeutics: This program utilizes an advanced ingestible smart capsule designed to deliver medications precisely within the gastrointestinal (GI) tract. The aim is to significantly improve therapies for inflammatory bowel diseases. Systemic Therapeutics: Through a specialized ingestible capsule, this initiative provides a needle-free method for administering biotherapeutics directly into the intestinal lining, thereby promoting more effective systemic absorption throughout the body. Furthermore, Biora is actively developing diagnostic devices. These tools are engineered to better characterize the digestive system and identify various GI conditions, such as small intestine bacterial overgrowth, by offering on-site diagnosis. Originally established in 2010 as Progenity, Inc., the company rebranded to Biora Therapeutics, Inc. in April 2022. This name change was made to reflect its concentrated strategic shift towards its therapeutics pipeline. Biora Therapeutics, Inc. is headquartered in San Diego, California.

Biora Therapeutics, Inc. is headquartered in US.

Biora Therapeutics, Inc. (BIOR) stock trades at $0.22 with a market capitalization of $994994. The stock is valued at a price-to-earnings (P/E) ratio of 0.00, price-to-book of 0.00, price-to-sales of 248.75. Over the past 52 weeks the stock has ranged between $0.15 and $0.38, and currently trades 42.1% below its 52-week high.

On profitability, Biora Therapeutics, Inc. generates a return on equity (ROE) of 121.86% — well above the market average, a sign of a high-quality business, return on capital employed of 211.43%.

Official website: www.bioratherapeutics.com